Factors influencing valproate pharmacokinetics in children and adults

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 11, 2010, Pages 767-775

  Jankovic, S M ^a   Milovanovic, J R ^a   Jankovic, S ^a  

^a University in Kragujevac   (Serbia)

Author keywords

Epilepsy; NONMEM; Population pharmacokinetics; Therapeutic drug monitoring; Valproate

Indexed keywords

CARBAMAZEPINE; EFTIL; EFTIL RETARD 500; LAMOTRIGINE; PHENOBARBITAL; UNCLASSIFIED DRUG; VALPROIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SERBIA; STEADY STATE; VALIDATION PROCESS;

EID: 78649291195     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48767     Document Type: Article

References (27)

1. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005; 32: 703-718.
2. Beal SL, Sheiner LB. NONMEM Users Guides. California: NONMEM Project Group, University of San Francisko; 1998.
3. Blanco Serrano B, Garcia Sanchez MJ, Otero MJ, Santos Buelga D, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999; 24: 73-80.
4. Blanco Serrano B, Otero MJ, Santos Buelga D, Garcia Sanchez MJ, Serrano J, Dominguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos. 1999; 20: 233-240.
5. Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther. 2004; 29: 105-120.
6. Botha JH, Gray AL, Miller R.Amodel for estimating individualized valproate clearance values in children. J Clin Pharmacol. 1995; 35: 1020-1024.
7. Correa T, Rodriquez I, Romano S. Population pharmacokinetics of Valproate in Mexican Children with epilepsy. Biopharm Drug Dispos. 2008; 29: 511-520.
8. Eadie MJ. Therapeutic drug monitoring-antiepileptic drugs. Br J Clin Pharmacol. 2001; 52: 11-20.
9. EL Desoky, Faseau E, EL Din Amry, Cosson V. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian patients. Eur J Clin Pharmacol. 2004; 59: 783-790.
10. Garcia MJ, Santos Bulega D, Otero MJ, Serrano J, Blanco B, Dominquez-Gil A. Population pharmacokinetics: effect of politherapy on valproic acid clearance. Abstr 657, 1997; www.page-meeting.org.
11. Jankovic SM, Milovanovic JR. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol. 2007; 29: 673-679.
12. Jiang DC, Wang L, Wang YQ, Li L, LU W, Bai XR. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharm Sinica. 2007; 28: 1677-1684. (Pubitemid 47493299)
13. Jiao Z, Zhong M-K, Shi X-J, Hu M, Zhang J. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit. 2003; 25: 279-286. (Pubitemid 36638170)
14. Johannessen CU, Johannessen SI.Valproate: past, present and future. CNS Drug Rev. 2003; 9: 199-216.
15. Kumps AH. Dose-dependency of the ratio between carbamazepine serum levels and dosage in patients with epilepsy. Ther Drug Monit. 1981; 3: 271-274. (Pubitemid 11031613)
16. LaRoche SM, Helmers SL. The new antiepileptic drugs. JAMA. 2004; 291: 605.
17. Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy. 1991; 11: 296-302.
18. Milovanovic JR, Jankovic SM. Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther. 2009; 47: 752-760.
19. Moris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998; 46: 547-551.
20. Murphy JE. Clinical pharmacokinetics pocket reference. Bethesda: American Society of Health- System Pharmacists; 2005.
21. Park HM, Kang SS, Lee YB, Shin DJ, Kim ON, Lee SB, Yim DS. Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther. 2002; 27: 419-425.
22. Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther. 2005; 30: 417-421.
23. Richens A. Pharmacokinetics of lamotrigine. In: Richens A (ed). Clinical update on lamotrigine: a novel antiepileptic agent. Kent: Wells Medical Limited; 1992. p. 21-27.
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9: 503-512.
25. Yukawa E, To H, Ohdo S, Higuchi S, Aoyma T. Detection of carbamazepine-induced changes in valpoic acid relative clearance in man by simple pharmacokinetic screening. J Pharm Pharmacol. 1997; 49: 751-756.
26. Yukawa E, To H, Ohdo S, Higuchi S Aoyama T. Population-based investigation of valproic acid relative clearence using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997; 37: 1160-1167. (Pubitemid 28076461)
27. Yukawa E. Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients. J Clin Pharm Ther. 1999; 24: 103-113.